The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $81.90

Today's change-6.30 -7.14%
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $81.90

Today's change-6.30 -7.14%
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc down (U.S.)$6.30

Vertex Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$6.30 or 7.14% to (U.S.)$81.90. Over the last five days, shares have lost 5.57% and are down 34.91% for the last year to date. This security has underperformed the S&P 500 by 33.43% during the last year.

Key company metrics

  • Open(U.S.) $83.58
  • Previous close(U.S.) $88.20
  • High(U.S.) $85.79
  • Low(U.S.) $81.82
  • Bid / Ask(U.S.) $0.00 / (U.S.) $81.90
  • YTD % change-34.91%
  • Volume2,298,494
  • Average volume (10-day)1,509,652
  • Average volume (1-month)1,551,829
  • Average volume (3-month)1,973,856
  • 52-week range(U.S.) $75.90 to (U.S.) $143.45
  • Beta0.53
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward77.18×
  • Forward PEG1.51×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.65
Updated June 24 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.69%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue398418310166
Total other revenue--------
Total revenue398418310166
Gross profit348356280151
Total cost of revenue50623015
Total operating expense412472380337
Selling / general / administrative1059710094
Research & development256310246224
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)1222
Other operating expenses, total1121
Operating income-14-54-70-171
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-31-76-92-191
Income after tax-36-75-94-221
Income tax, total5-1130
Net income-42-74-95-189
Total adjustments to net income--------
Net income before extra. items-42-74-95-189
Minority interest-61-132
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-74-95-189
Inc. avail. to common incl. extra. items-42-74-95-189
Diluted net income-42-74-95-189
Dilution adjustment--------
Diluted weighted average shares244243242241
Diluted EPS excluding extraordinary itemsvalue per share-0.17-0.30-0.39-0.78
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.17-0.30-0.39-0.78